

Figure S1. Transduction of lentiviral Kidins220 shRNAs (sh2: GGCCTGCAAGATCCAATTATA and sh6: CGAGTATTCAAGACTGAAGAT) in PANC1 and Mia PaCa 2 cell lines. qPCR was performed to determine the Kidins220 transcripts in the transduced cell lines (A and B). Kidins220 sh2 resulted in a reduction in the Kidins220 expression in the two cell lines which were used in the present study. Kidins220 sh6 only resulted in a reduced expression of Kidins220 in PANC1 cells. However, it had a similar effect on the expression of EGFR (C), E-cadherin and Snail (D) as observed in cell lines with Kidins220 knockdown using the Kidins220 sh2. **P<0.01 and ***P<0.001.




Table SI. Primer sequences.

Primer name	Primer sequence (5'-3')	Product size (bp)
<i>GAPDHF8</i>	GGCTGCTTTTAACTCTGGTA	475
<i>GAPDHR8</i>	GACTGTGGTCATGAGTCCTT	
<i>Kidins220F2</i>	AGACGTTCCATGCTCAGA	539
	CTCGAGCCACAAGAACTG	
<i>Kidins220ZR2</i>	ACTGAACCTGACCGTACATGCCTTCTTCGGTAAGTG	136
<i>EGFRF1</i>	AGAGTCTCAAAGCCATGTTAT	
<i>EGFRZR1</i>	ACTGAACCTGACCGTACACCATCCTAAGCATGACTCC	120
<i>E-cadF22</i>	CAGGAGCCAGACACATTTAT	
<i>E-cadR22</i>	TCTAAGGTGGTCACTTGGTC	515
<i>SnailF11</i>	CGCTCTTTCCTCGTCAG	
<i>SnailR11</i>	GTTGCAGTATTTGCAGTTGA	474
<i>NF-Kb1F1</i>	CTGGCAGGTATTTGACATATT	
<i>NF-kB1ZR1</i>	ACTGAACCTGACCGTACAAGCTGTTTCATGTCTCCTTG	90
<u><i>GAPDHSGF1</i></u>	TGCACCACCAACTGCTTAGC	
<u><i>GAPDHSGR1</i></u>	GGCATGGACTGTGGTCATGAG	87
<u><i>MMP1SGF1</i></u>	GGGAGATCATCGGGACAACCTC	
<i>MMP1SGR1</i>	GGGCCTGGTTGAAAAGCAT	72

Table SII. Expression of Kidins220 in pancreatic cancer.

Variable	N	Mean $\pm$ SEM (copies/50 ng RNA)	P-value
Clinical samples			
Tumor	149	75.150 $\pm$ 5,76,945	0.029
Normal	145	2.13 E+12 $\pm$ 9.62 E+11	
Gentle			
Male	89	11,4106 $\pm$ 96,478	0.32
Female	60	17,365 $\pm$ 6,882	
Node status			
Node negative	56	1,68,646 $\pm$ 1,53,0096	0.32
Node positive	81	13,872 $\pm$ 5,124	
Differentiation			
High	9	1,305 $\pm$ 1,299	0.056
Moderate	53	12,778 $\pm$ 5,732	
Poor	10	1,767 $\pm$ 1,226	
Histology			
Adeno	61	82,114 $\pm$ 65,598	0.39
Ductal	6	22,796 $\pm$ 22,739	
Others	10	26,053 $\pm$ 24,104	
TNM staging			
1-2	114	20,490 $\pm$ 6,680	0.0034
3-4	19	519 $\pm$ 226	
Clinical outcomes			
Dead	108	99,489 $\pm$ 7,95,413	0.28
Alive	33	13,124 $\pm$ 73,627	
Metastasis			
Yes	10	614 $\pm$ 338	0.2
No	139	80,512 $\pm$ 61,835	

Table SIII. Predictive miRNAs targeting Kidins220 and its correlation with Kidins220 expression in the TCGA pancreatic cancer cohort.

Variable	miRTarBase		Correlation (n=178)
	P-value	Combined score	Spearman
miR-423-3p	0.0115	390.37	r=-0.183 P=0.0145
miR-4638-5p	0.0113	359.37	N/A
miR-223-3p	0.0150	281.14	r=-0.0971 P=0.197
miR-30a-5p	0.0367	90.21	r=-0.0318 P=0.673
miR-192-5p	0.0497	60.48	r=-0.169 P=0.0244
miR-7b-5p	0.0601	46.16	r=0.238 P=0.0014
miR-16-5p	0.0778	32.85	r=-0.285 P=0.0001

Prediction of miRNA targeting Kidins220 was performed using the miRTarbase 2017 at the Enrichr platform (<https://amp.pharm.mssm.edu/Enrichr/>) (29). Correlation between the predicted miRNAs and Kidins220 in the TCGA PAAD cohort was determined using Spearman test.